期刊
EUROPEAN HEART JOURNAL
卷 40, 期 23, 页码 1850-1858出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehz103
关键词
Arrhythmogenic right ventricular cardiomyopathy; Implantable cardioverter-defibrillators; Sudden cardiac death; Ventricular arrhythmias
资金
- Canadian Heart Rhythm Society George Mines Traveling Fellowship
- Montreal Heart Institute Foundation 'Bal du Coeur' bursary
- Fondation Leducq [16 CVD 02]
- Dutch Heart Foundation [2015T058]
- Netherlands Organisation for Scientific Research [040.11.586]
- Netherlands Heart Institute [06901]
- Swiss National Science Foundation [320030_160327]
- UMC Utrecht 2017 Alexandre Suerman Stipend
- UMC Utrecht Fellowship Clinical Research Talent
- European Union's Horizon 2020 research and innovation program under the ERA-NET Co-fund action [680969]
- Dr Francis P. Chiaramonte Private Foundation
- Leyla Erkan Family Fund for ARVD Research
- Dr Satish, Rupal, and Robin Shah ARVD Fund at Johns Hopkins
- Bogle Foundation
- Healing Hearts Foundation
- Peter French Memorial Foundation
- Wilmerding Endowments
- Georg und Bertha Schwyzer-Winiker Foundation
- Baugarten Foundation
- Swiss Heart Foundation
- Leonie-Wild Foundation
- Marvin and Philippa Carsley Chair of Medicine
- UCL Hospitals NIHR Biomedical Research Centre
- H2020 Societal Challenges Programme [680969] Funding Source: H2020 Societal Challenges Programme
- Swiss National Science Foundation (SNF) [320030_160327] Funding Source: Swiss National Science Foundation (SNF)
Aims Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients. Methods and results Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 +/- 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44-9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73-0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92-0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.6% reduction of ICD placements with the same proportion of protected patients (P < 0.001). Conclusion Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据